Induction therapy in pediatric renal transplant recipients: An overview

Pediatric Drugs

Volumn 9, Issue 5, 2007, Pages 323-341

  Moudgil, Asha ^a   Puliyanda, Dechu ^b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Alemtuzumab, therapeutic use; Antithymocyte globulin, therapeutic use; Basiliximab, therapeutic use; Belatacept, therapeutic use; Children; Ciclosporin, therapeutic use; Corticosteroids, therapeutic use; Daclizumab, therapeutic use

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; FINGOLIMOD; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; ORTHOCLONE; PLACEBO; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ANEMIA; ASEPTIC MENINGITIS; B LYMPHOCYTE; BACTERIAL INFECTION; BLOOD GROUP; BRAIN EDEMA; CATARACT; CHILL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTINUOUS INFUSION; CYTOKINE RELEASE SYNDROME; CYTOMEGALIC INCLUSION BODY DISEASE; CYTOMEGALOVIRUS INFECTION; DATA ANALYSIS; DIARRHEA; DONOR; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EXPERIMENTAL THERAPY; FEVER; GOUT; GRAFT FAILURE; GRAFT INFECTION; GRAFT RECIPIENT; GRAFT SURVIVAL; GROWTH RETARDATION; GUM HYPERPLASIA; HEADACHE; HEMOLYTIC UREMIC SYNDROME; HIGH RISK PATIENT; HIRSUTISM; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERPLASIA; HYPERTENSION; HYPOGAMMAGLOBULINEMIA; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LUNG EDEMA; LYMPH NODE IRRADIATION; LYMPHOCYTE; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; MORBIDITY; MYALGIA; NEPHROTOXICITY; NONHUMAN; OSTEOPENIA; OUTCOME ASSESSMENT; PEDIATRICS; POPULATION; PRIORITY JOURNAL; PROTEIN DEFECT; RECOMMENDED DRUG DOSE; REGISTER; REVIEW; RISK; SEIZURE; SIDE EFFECT; SODIUM RETENTION; STANDARD; STOMACH ULCER; T LYMPHOCYTE; TARGET CELL; THROMBOCYTOPENIA; TREMOR; UNITED STATES; URINARY TRACT INFECTION; VOMITING; WATER RETENTION; WOUND HEALING IMPAIRMENT;

EID: 35048869532     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200709050-00005     Document Type: Review

References (108)

1. Grigoryev DN, Liu M, Cheadle C, et al. Genomic profiling of kidney ischemia-reperfusion reveals expression of specific alloimmunity-associated genes: Linking "immune" and "nonimmune" injury events. Transplant Proc 2006; 38: 3333-6
2. Sandrini S. Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: a review. Clin Transplant 2005; 19: 705-10
3. Shaffer D, Langone A, Nylander WA. A pilot protocol of a calcineurin-inhibitor free regimen for kidney transplant recipients of marginal donor kidneys or with delayed graft function. Clin Transplant 2003; 17 Suppl. 9: 31-4
4. Ettenger RB. Children are different: the challenges of pediatric renal transplantation. Am J Kidney Dis 1992; 20: 668-72
5. Ettenger RB. Age and the immune response in pediatric renal transplantation. Eur J Pediatr 1992; 151 Suppl. 1: S7-8
6. Ettenger RB, Blifeld C, Prince H, et al. The pediatric nephrologist's dilemma: growth after renal transplantation and its interaction with age as a possible immunologic variable. J Pediatr 1987; 111: 1022-5
7. Najarian JS, Ferguson RM, Sutherland DE, et al. Fractionated total lymphoid irradiation as preparative immunosuppression in high risk renal transplantation: clinical and immunological studies. Ann Surg 1982; 196: 442-52
8. Levin B, Hoppe RT, Collins G, et al. Treatment of cadaveric renal transplant recipients with total lymphoid irradiation, antithymocyte globulin, and low-dose prednisone. Lancet 1985; II: 1321-5
9. Slavin S, Strober S, Fuks Z, et al. Immunosuppression and organ transplantation tolerance using total lymphoid irradiation. Diabetes 1980; 29 Suppl. 1: 121-3
10. Myburgh JA, Smit JA, Stark JH, et al. Total lymphoid irradiation in kidney and liver transplantation in the baboon: prolonged graft survival and alterations in T cell subsets with low cumulative dose regimens. J Immunol 1984; 132: 1019-25
11. Millan MT, Shizuru JA, Hoffmann P, et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation 2002; 73: 1386-91
12. Field EH, Strober S. Tolerance, mixed chimerism and protection against graft-versus-host disease after total lymphoid irradiation. Philos Trans R Soc Lond B Biol Sci 2001; 356: 739-48
13. Bourdage JS, Hamlin DM. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 1995; 59: 1194-200
14. Woodside KJ, Hu M, Gugliuzza KK, et al. T-lymphocyte apoptosis is increased by non-interleukin-2-dependent induction in human mixed lymphocyte cultures. Transplant Proc 2005; 37: 1949-52
15. Najarian JS, Simmons RL, Condie RM, et al. Seven years' experience with antilymphoblast globulin for renal transplantation from cadaver donors. Ann Surg 1976; 184: 352-68
16. Sutherland DE, Fryd DS, Strand MH, et al. Results of the Minnesota randomized prospective trial of cyclosporine versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients. Am J Kidney Dis 1985; 5: 318-27
17. Johnson CP, Simmons RL, Sutherland DE, et al. A randomized trial comparing cyclosporine with antilymphoblast-globulin-azathioprine for renal allograft recipients: results at 2 1/2-6 years. Transplantation 1988; 45: 380-5
18. Kupin WL, Venkatachalam KK, Oh HK, et al. Sequential use of Minnesota antilymphoblast globulin and cyclosporine in cadaveric renal transplantation. Transplantation 1985; 40: 601-4
19. Stratta RJ, D'Alessandro AM, Armbrust MJ, et al. Sequential antilymphocyte globulin/cyclosporine immunosuppression in cadaveric renal transplantation: effect of duration of ALG therapy. Transplantation 1989; 47: 96-102
20. Almond PS, Matas AJ, Gillingham K, et al. Pediatric renal transplants: results with sequential immunosuppression. Transplantation 1992; 53: 46-51
21. Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of Thymoglobulin versus ATGAM for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67: 1011-8
22. Hardinger KL, Schnitzler MA, Miller B, et al. Five-year follow-up of thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation 2004; 78: 136-41
23. Ault BH, Honaker MR, Osama Gaber A, et al. Short-term outcomes of thymoglobulin induction in pediatric renal transplant recipients. Pediatr Nephrol 2002; 17: 815-8
24. Khositseth S, Matas A, Cook ME, et al. Thymoglobulin versus ATGAM induction therapy in pediatric kidney transplant recipients: a single-center report. Transplantation 2005; 79: 958-63
25. Brophy PD, Thomas SE, McBryde KD, et al. Comparison of polyclonal induction agents in pediatric renal transplantation. Pediatr Transplant 2001; 5: 174-8
26. Colleen Hastings M, Wyatt RJ, Lau KK, et al. Five years' experience with thymoglobulin induction in a pediatric renal transplant population. Pediatr Transplant 2006; 10: 805-10
27. Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration: systemic cytokine release and modulation by corticosteroids. Transplantation 1990; 49: 697-702
28. Ettenger R, Marik J, Rosenthal JT. Sequential therapy in pediatric cadaveric renal transplantation: a critical analysis. J Am Soc Nephrol 1992; 2 (12 Suppl.): S304-11
29. Norman DJ, Kahana L, Stuart FP, et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993; 55: 44-50
30. Goldman M, Abramowicz D, De Pauw L, et al. Beneficial effects of prophylactic OKT3 in cadaver kidney transplantation: comparison with cyclosporin A in a single-center prospective randomized study. Transplant Proc 1991; 23: 1046-7
31. Caillard S, Dharnidharka V, Agodoa L, et al. Post transplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80: 1233-43
32. Benfield MR, Tejani A, Harmon WE, et al. A randomized multicenter trial of OKT3 mAbs induction compared with intravenous cyclosporine in pediatric renal transplantation. Pediatr Transplant 2005; 9: 282-92
33. Ettenger RB, Rosenthal JT, Marik JL, et al. Improved cadaveric renal transplant outcome in children. Pediatr Nephrol 1991; 5: 137-42
34. Bartosh SM, Aronson AJ, Swanson-Pewitt EE, et al. OKT3 induction in pediatric renal transplantation. Pediatr Nephrol 1993; 7: 45-9
35. NAPRTCS [online]. Available from URL: https://web.emmes.com/study/ped/ ann-lrept [Accessed 2007 Jun 27]
36. Di Filippo S. Anti-IL-2 receptor antibody vs. polyclonal anti-lymphocyte antibody graftas induction therapy in pediatric transplantation. Pediatr Transplant 2005; 9: 373-80
37. Baudouin V, Crusiaux A, Haddad E, et al. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab. Transplantation 2003; 76: 459-63
38. Nashan B, Moore R, Amlot P, et al. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients: CHIB 201 International Study Group. Lancet 1997; 350: 1193-8
39. Kovarik JM, Kahan BD, Rajagopalan PR, et al. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation: the US Simulect Renal Transplant Study Group. Transplantation 1999; 68: 1288-94
40. Thistlethwaite Jr JR, Nashan B, Hall M, et al. Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus: the Global Simulect Study Group. Transplantation 2000; 70: 784-90
41. Ponticelli C, Yussim A, Cambi V, et al. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 2001; 72: 1261-7
42. Bumgardner GL, Hardie I, Johnson RW, et al. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation 2001; 72: 839-45
43. Nashan B, Light S, Hardie IR, et al. Reduction of acute renal allograft rejection by daclizumab: Daclizumab Double Therapy Study Group. Transplantation 1999; 67: 110-5
44. Haririan A, Morawski K, Sillix DH, et al. Induction therapy with basiliximab versus Thymoglobulin in African-American kidney transplant recipients. Transplantation 2005; 79: 716-21
45. Mourad G, Rostaing L, Legendre C, et al. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 2004; 78 (4): 584-90
46. Sollinger HW. A few memories from the beginning. Transplantation 2005; 80 (2 Suppl.): S178-80
47. Lebranchu Y, Bridoux F, Buchler M, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002; 2: 48-56
48. Brennan DC, Daller JA, Lake KD, et al. Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967-77
49. Lin M, Ming A, Zhao M. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study. Clin Transplant 2006; 20: 325-9
50. Swiatecka-Urban A. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status. Pediatr Drugs 2003; 5: 699-716
51. Garcia CD, Barros VR, Schneider L, et al. IL-2 antibody induction and the outcome of pediatric renal transplants. Transplant Proc 2002; 34: 2914-5
52. Garcia Meseguer C, Vila Lopez A, Luque de Pablos A, et al. Immunoprophylaxis with Simulect (basiliximab) in pediatric kidney transplant recipients: results from routine clinical practice at 5 kidney transplant units. Transplant Proc 2003; 35: 1697-8
53. Ciancio G, Burke GW, Suzart K, et al. Effect of daclizumab, tacrolimus, and mycophenolate mofetil in pediatric first renal transplant recipients. Transplant Proc 2002; 34: 1944-5
54. Benfield MR, Ping-Leung H. Comparative study of the safety, efficacy, and practice patterns of monoclonal antibodies in pediatric renal transplantation [abstract]. Am J Transplant 2002; 2 (Suppl. 3): S192
55. Smith JM, Stablein D, Singh A, et al. Decreased risk of renal allograft thrombosis associated with interleukin-2 receptor antagonists: a report of the NAPRTCS. Am J Transplant 2006; 6: 585-8
56. Clark G, Walsh G, Deshpande P, et al. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation. Nephrol Dial Transplant 2002; 17: 1304-9
57. Hubsch H, Montane B, Abitbol C, et al. Recurrent focal glomerulosclerosis in pediatric renal allografts: the Miami experience. Pediatr Nephrol 2005; 20: 210-6
58. Strehlau J, Pape L, Offner G, et al. Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients. Lancet 2000; 356: 1327-8
59. Calne R, Moffat SD, Friend PJ, et al. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999; 68: 1613-6
60. Knechtle SJ, Pirsch JD, Fechner Jr HJ, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3: 722-30
61. Borrows R, Loucaidou M, Van Tromp J, et al. Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation. Am J Transplant 2004; 4: 1845-51
62. Flechner SM, Friend PJ, Brockmann J, et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant 2005; 5: 3009-14
63. Ciancio G, Burke GW, Gaynor JJ, et al. The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation 2004; 78: 426-33
64. Tan HP, Kaczorowski DJ, Basu A, et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2006; 10: 2409-17
65. Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (Campath 1H) induction therapy in cadaveric kidney transplantation: efficacy and safety at five years. Am J Transplant 2005; 5: 1347-53
66. Knechtle SJ, Fernandez LA, Pirsch JD, et al. Campath-1H in renal transplantation: the University of Wisconsin experience. Surgery 2004; 136: 754-60
67. Kaufman DB, Leventhal JR, Axelrod D, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction: long-term results. Am J Transplant 2005; 5: 2539-48
68. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005; 80: 457-65
69. Vo AA, Lukovsky M, Toyoda M, et al. Efficacy and safety profile of subcutaneous Campath 1H administration in cross match positive patients desensitized with intravenous immunoglobulin. Am J Transplant 2006; 6 Suppl. 2: 291-2
70. Shapiro R, Ellis D, Tan HP, et al. Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation. J Pediatr 2006; 148: 813-8
71. Bartosh SM, Knechtle SJ, Sollinger HW. Campath-1H use in pediatric renal transplantation. Am J Transplant 2005; 5: 1569-73
72. U.S. National Institutes of Health. Safety of a multitherapy regimen containing alemtuzumab in children and adolescents after kidney transplantation [online]. Available from URL: http://www.clinicaltrials.gov/ct/gui/show/ NCT00240994 [Accessed 2007 Jun 29]
73. Luo G, Falta EM, Elster EA. Steroid-free immunosuppression in organ transplantation. Curr Diab Rep 2005; 5: 305-10
74. Birkeland SA. Steroid-free immunosuppression in renal transplantation. Lancet 1996; 348: 1105-6
75. Birkeland SA. Steroid-free immunosuppression after kidney transplantation with antithymocyte globulin induction and cyclosporine and mycophenolate mofetil maintenance therapy. Transplantation 1998; 66: 1207-10
76. Birkeland SA. Steroid-free immunosuppression in renal transplantation: a long-term follow-up of 100 consecutive patients. Transplantation 2001; 71: 1089-90
77. Laftavi MR, Lefrancois LN, Dagher F, et al. Steroid withdrawal is associated with more chronic allograft nephropathy (CAN) following kidney transplantation [abstract no. 518]. Annual meeting of the American Transplant Congress; 2005 May 21-25; Seattle (WA)
78. Birkeland SA, Larsen KE, Rohr N. Pediatric renal transplantation without steroids. Pediatr Nephrol 1998; 12: 87-92
79. Sarwal MM, Vidhun JR, Alexander SR, et al. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 2003; 76 (9): 1331-9
80. Morris P. Kidney transplantation, principles and practice. 4th ed. Philadelphia (PA): W.B. Saunders, 1994
81. Willetts IE, Trompeter RS. Experience with cyclosporine in pediatric renal renal transplantation. Transplant Proc 2004; 36 (2 Suppl.): 211S-5S
82. Shapiro R, Scantlebury VP, Jordan ML, et al. Pediatric renal transplantation under tacrolimus-based immunosuppression. Transplantation 1999; 67: 299-303
83. Dharnidharka VR, Sullivan EK, Stablein DM, et al. Risk factors for post-transplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001; 71: 1065-8
84. Caillard S, Dharnidharka V, Agodoa L, et al. Post-transplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005 Nov 15; 80 (9): 1233-43
85. Dharnidharka VR, Ho PL, Stablein DM, et al. Mycophenolate, tacrolimus and posttransplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 2002; 5: 396-9
86. First MR, Gerber DA, Hariharan S, et al. Post-transplant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management. Transplant 2002; 73: 379-86
87. Ciancio G, Lo Monte A, Buscemi G, et al. Use of tacrolimus and mycophenolate mofetil as induction and maintenance in simultaneous pancreas-kidney transplantation. Transpl Int 2000; 13 Suppl. 1: S191-4
88. Shapiro R, Scantlebury V, Jordan ML, et al. Post-transplant diabetes in pediatric recipients on tacrolimus [letter]. Transplantation 1999 Mar 15; 67 (5): 771
89. Shapiro R, Scantlebury VP, Jordan ML, et al. Pediatric renal transplantation under tacrolimus-based immunosuppression. Transplantation 1999; 67: 299-303
90. Jordan SC, Vo AA, Pang A, et al. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 2006; 6: 459-66
91. Jordan SC, Tyan D, Czer L, et al. Immunomodulatory actions of intravenous immunoglobulin (IVIG): potential applications in solid organ transplant recipients. Pediatr Transplant 1998; 2: 92-105
92. O'Dwyer ME, Launder T, Rabkin JM, et al. Successful treatment of aggressive post-transplant lymphoproliferative disorder using rituximab. Leuk Lymphoma 2000; 39: 411-9
93. Tyden G, Kumlien G, Genberg H, et al. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005; 5: 145-8
94. Donauer J, Wilpert J, Geyer M, et al. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a single center experience. Xenotransplantation 2006; 13: 108-10
95. Sawada T, Fuchinoue S, Teraoka S. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation 2002; 74: 1207-10
96. Gloor JM, DeGoey SR, Pineda AA, et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003; 3: 1017-23
97. Sawada T, Fuchinoue S, Kawase T, et al. Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy and DFPP-enabled non-responders to undergo ABO-incompatible kidney transplantation. Clin Transplant 2004; 18: 254-60
98. Sonnenday CJ, Warren DS, Cooper M, et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004; 8: 1315-22
99. Segev D, Simpkins CE, Warren DS, et al. ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment. Am J Transplant 2005; 10: 2570-5
100. Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 2004; 4: 1019-25
101. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770-81
102. Kunzendorf U, Ziegler E, Kabelitz D. FTY720: the first compound of a new promising class of immunosuppressive drugs. Nephrol Dial Transplant 2004; 19: 1677-81
103. Tedesco-Silva H, Mourad G, Kahan BD, et al. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 2005; 79: 1553-60
104. Tedesco-Silva H, Pescovitz MD, Cibrik D, et al., for the FTY720 Study Group. Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation 2006; 82: 1689-97
105. Budde K, Schütz M, Glander P, et al. FTY720 (fingolimod) in renal transplantation. Clin Transplant 2006; 20 Suppl. 17: 17-24
106. Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg 2005; 200: 505-15; quiz A59-61
107. Bunnapradist S, Takemoto SK. Multivariate analysis of antibody induction therapy and their associated outcomes in deceased donor transplants. Transplant Proc 2005; 37: 889-91
108. Puliyanda DP, Stablein DM, Dharnidharka VR. Younger age and antibody induction increase the risk for infection in pediatric renal transplantation: a NAPRTCS report. Am J Transplant 2007; 3: 662-6